This is a working overview of melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-04 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
In her ruling, she cited Jacobson v Massachusetts, a 1905 U.S. Supreme Court case that upheld the authority of U.S. states to compel people to get vaccinations. On March 25, 2020, Pritzker announced the extension of Illinois's tax filing deadline from April 15 to July 15. He also announced three new emergency assistance programs that allowed small businesses to access more than $90 million in aid. On April 23, 2020, Pritzker extended the stay-at-home order through May 29 with some modifications. Churches were prohibited from holding meetings that had more than 10 people in attendance. Some churches defied Pritzker, held meetings, and filed federal lawsuits. On May 1, 2020, Pritzker enacted a statewide mask mandate. On May 5, 2020, Pritzker announced his reopening plan, "Restore Illinois". The plan had five phases and split the state's 11 existing Emergency Medical Services Regions into four reopening regions. The regions could reopen independently of one another. All regions were then in Phase Two, which allowed retail curbside pickup and delivery along with outdoor activities such as golf, boating, and fishing. Phase Three would allow manufacturing, offices, retail, barbershops, and salons to reopen with capacity limits, along with gatherings of fewer than 10 people. In Phase 4, gatherings of up to 50 people were allowed, restaurants and bars could reopen, travel resumed, and child care and schools reopened under guidance from the IDPH. In Phase 5, the economy fully reopened.
But it did get a little close there for a while. As you may know, there were 61 planes in the air headed toward Haïti at the time they finally agreed. And at one point General Biamby came in and told General Cédras that he had just gotten word on his telephone that the airplanes had taken off from Pope Air Force Base, with soldiers from Fort Bragg, and that both disconcerted them and caused them to be suspicious of the intent of the negotiations, but it also created a situation where immediately after that, the key points they had been refusing to agree to were agreed to, a date certain, other matters that I won't go into in detail here.
Early cephalopods are thought to have produced jets by drawing their body into their shells, as Nautilus does today. Nautilus is also capable of creating a jet by undulations of its funnel; this slower flow of water is more suited to the extraction of oxygen from the water. When motionless, Nautilus can only extract 20% of oxygen from the water. The jet velocity in Nautilus is much slower than in coleoids, but less musculature and energy is involved in its production. Jet thrust in cephalopods is controlled primarily by the maximum diameter of the funnel orifice (or, perhaps, the average diameter of the funnel) and the diameter of the mantle cavity. Changes in the size of the orifice are used most at intermediate velocities. The absolute velocity achieved is limited by the cephalopod's requirement to inhale water for expulsion; this intake limits the maximum velocity to eight body-lengths per second, a speed which most cephalopods can attain after two funnel-blows. Water refills the cavity by entering not only through the orifices, but also through the funnel. Squid can expel up to 94% of the fluid within their cavity in a single jet thrust. To accommodate the rapid changes in water intake and expulsion, the orifices are highly flexible and can change their size by a factor of 20; the funnel radius, conversely, changes only by a factor of around 1.5. Some octopus species are also able to walk along the seabed. Squids and cuttlefish can move short distances in any direction by rippling of a flap of muscle around the mantle. While most cephalopods float (i.e.
Some individuals inherit DQ2.5 from one parent and an additional portion of the haplotype (either DQB1*02 or DQA1*05) from the other parent, increasing risk. Less commonly, some individuals inherit the DQA1*05 allele from one parent and the DQB1*02 from the other parent (DQ2.5trans), and these individuals are at similar risk of coeliac disease as those with a single DQ2.5-bearing chromosome 6. Among those with coeliac disease who do not have DQ2.5 (cis or trans) or DQ8 (encoded by the haplotype DQA1*03:DQB1*0302), 2-5% have the DQ2.2 isoform, and the remaining 2% lack DQ2 or DQ8. Other genetic factors have been reported in coeliac disease, but involvement in the disease has variable geographic recognition. Only the HLA-DQ loci show a consistent involvement across the global population. Many of the detected loci are associated with other autoimmune diseases. The prevalence of the HLA-DQ2 genotype and gluten consumption has increased over time. Since untreated coeliac disease can cause serious health problems and affect fertility, it would be expected that HLA-DQ2 and HLA-DQ8 would become less common. The opposite is true—they are most common in areas where gluten-rich foods have been eaten for thousands of years. The HLA-DQ2 gene may have been genetically favoured in the past because it helps protect against tooth decay.
Sources: en.wikipedia.org
== Ceramide phosphoethanolamine == Ceramide phosphoethanolamine (CPE) is a sphingolipid consisted of a ceramide and a phosphoethanolamine head group. CPE is the major sphingolipid class in some invertebrates such as members of Drosophila. In contrast, mammalian cells contain only small amounts of CPE.
== Signs and symptoms == In a 2021 article on Sjögren's patients, a majority of individuals stated that eight symptoms had a major or moderate impact on their life: fatigue (79%); dry eyes (75%); dry mouth (73%); joint pain (65%); trouble sleeping (64%); eye discomfort (60%); muscle pain (56%); and brain fog (54%). Primary symptoms are dryness (dry mouth and dry eyes), pain and fatigue. Other symptoms can include dry skin, vaginal dryness, a chronic cough, numbness in the arms and legs, feeling tired, muscle and joint pains, and thyroid problems. Those affected are also at an increased risk (5%) of lymphoma.
=== Cardiomyopathies === Cardiomyopathies are generally inherited as autosomal dominants, although recessive forms have been described, and dilated cardiomyopathy can also be inherited in an X-linked pattern. Consequently, in addition to tragedy involving an athlete who succumbs, there are medical implications for close relatives. Among family members of index cases, more than 300 causative mutations have been identified. However, not all mutations have the same potential for severe outcomes, and there is not yet a clear understanding of how these mutations (which affect the same myosin protein molecule) can lead to the dramatically different clinical characteristics and outcomes associated with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). Since HCM, as an example, is typically an autosomal dominant trait, each child of an HCM parent has a 50% chance of inheriting the mutation. In individuals without a family history, also known as sporadic cases, a common cause of the disease may be a "de novo" mutation of the gene that produces the β-myosin heavy chain, with two out of seven tested patients falling into this category.
Tyrosine or its precursor N-acetyl-L-tyrosine are commonly used to purportedly boost levels of dopamine and noradrenaline. Some brands may contain L-dopa (generally as Mucuna pruriens extract), but this is classified as a prescription medicine in many countries. Theanine is often used as an ingredient (sometimes as "green tea extract", though this may alternatively be used to refer to EGCG, which may also be present), to supposedly improve mental and physical performance, and reduce anxiety. Piperine (often as "black pepper extract") is often included possibly to improve absorption of other ingredients, and for its supposed ability to improve muscle recovery. B vitamins are another common ingredient, most commonly vitamin B3 and vitamin B12 in various forms, but also often thiamine (sometimes as sulbutiamine), pantothenic acid (vitamin B5) and folic acid. Carnitine or its precursor acetylcarnitine are sometimes added to the mix for their supposed ability to enhance exercise performance and aid recovery, though evidence for these benefits is weak. Betaine (trimethylglycine) is often used as an ingredient, despite limited evidence for effectiveness in increasing athletic performance. Phenethylamines such as β-phenethylamine, β-methylphenethylamine, deterenol, halostachine, N-methyltyramine, hordenine, or synephrine (sometimes as "bitter orange extract") may be included as thermogenics to aid in weight loss. Higenamine (norcoclaurine) is also often added for its supposed weight loss and mild stimulant properties.
Additionally, in January 1978, the band appeared as themselves in two episodes of the ABC sitcom What's Happening!!, performing "Echoes of Love," "Little Darlin' (I Need You)", "Black Water", "Takin' It to the Streets", and "Take Me in Your Arms". Performances were done live (versus lip synching to a pre-recorded track), with some overdubs added in post production, notably during Baxter's solo on "Take Me in Your Arms (Rock Me a Little While)," which was lifted from the album version. After almost a decade on the road, and with seven albums to their credit, the Doobies' profile was substantially elevated by the success of their next album, 1978's Minute by Minute. It spent five weeks atop the charts and dominated several radio formats for the better part of two years. McDonald's song "What a Fool Believes", written with Kenny Loggins, was the band's second No. 1 single and earned the songwriting duo (along with producer Ted Templeman) a Grammy Award for Record of the Year. The album won a Grammy for Pop Vocal Performance by a Group and was nominated for Album of the Year. Both "What a Fool Believes" and the title track were nominated for Song of the Year, with "What a Fool Believes" winning the award. Among the other memorable songs on the album are "Here to Love You", "Dependin' On You" (co-written by McDonald and Simmons), "Steamer Lane Breakdown" (a Simmons bluegrass instrumental) and McDonald's "How Do the Fools Survive?" (co-written by Carole Bayer Sager). Nicolette Larson and departed former bandleader Johnston contributed guest vocals on the album.
Sources: en.wikipedia.org
In addition, two forms of albinism, with approximately 1 in 2,700 most prevalent among people of Puerto Rican origin, are associated with mortality beyond melanoma-related deaths. The connection between albinism and deafness is well known, though poorly understood. In his 1859 treatise On the Origin of Species, Charles Darwin observed that "cats which are entirely white and have blue eyes are generally deaf". In humans, hypopigmentation and deafness occur together in the rare Waardenburg's syndrome, predominantly observed among the Hopi in North America. The incidence of albinism in Hopi Indians has been estimated as approximately 1 in 200 individuals. Similar patterns of albinism and deafness have been found in other mammals, including dogs and rodents. However, a lack of melanin per se does not appear to be directly responsible for deafness associated with hypopigmentation, as most individuals lacking the enzymes required to synthesize melanin have normal auditory function. Instead, the absence of melanocytes in the stria vascularis of the inner ear results in cochlear impairment, though the reasons for this are not fully understood. In Parkinson's disease, a disorder that affects neuromotor functioning, there is decreased neuromelanin in the substantia nigra and locus coeruleus as a consequence of specific dropping out of dopaminergic and noradrenergic pigmented neurons. This results in diminished dopamine and norepinephrine synthesis.
== Categories defined by Kardashev == The hypothetical classification, known as the Kardashev scale, distinguishes three stages in the evolution of civilizations according to the dual criteria of access and energy consumption. The purpose of this classification is to guide the search for extraterrestrial civilizations, particularly within SETI, in which Kardashev participated, and this on the assumption that a fraction of the energy used by each type is intended for communication with other civilizations. To make this scale more understandable, Lemarchand compares the speed at which a volume of information equivalent to 100,000 average-sized books can be transmitted across the galaxy. A Type II civilization can send this data using a transmission beam that lasts for only 100 seconds. A similar amount of information can be sent across intergalactic distances of about 10 million light-years, with a transmission time of several weeks. A Type III civilization can send the same amount of data to the entire observable universe with a transmission time of 3 seconds. Kardashev's classification is based on the assumption of a growth rate of 1% per year. Kardashev believed that it would take humanity 3,200 years to reach Type II, and 5,800 years to reach Type III. However, Dr. Michio Kaku believes that humanity must increase its energy consumption by 3% per year to reach Type I in 100–200 years. These types are thus separated from each other by a growth rate of several billion.
==== Other materials ==== Paraffin wax does not always provide a sufficiently hard matrix for cutting very thin sections (which are especially important for electron microscopy). Paraffin wax may also be too soft in relation to the tissue, the heat of the melted wax may alter the tissue in undesirable ways, or the dehydrating or clearing chemicals may harm the tissue. Alternatives to paraffin wax include, epoxy, acrylic, agar, gelatin, celloidin, and other types of waxes. In electron microscopy epoxy resins are the most commonly employed embedding media, but acrylic resins are also used, particularly where immunohistochemistry is required. For tissues to be cut in a frozen state, tissues are placed in a water-based embedding medium. Pre-frozen tissues are placed into molds with the liquid embedding material, usually a water-based glycol, OCT, TBS, Cryogen, or resin, which is then frozen to form hardened blocks.
== Further reading == Carson C, Faria G, Hellstrom WJ, Krishnamurti S, Minhas S, Moncada I, et al. (1 January 2010). "Implants, Mechanical Devices, and Vascular Surgery for Erectile Dysfunction". Journal of Sexual Medicine. 7 (1). Wiley: 501–523. doi:10.1111/j.1743-6109.2009.01626.x. PMID 20092450.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.